Overview

Imaging With [89Zr]Panitumumab-PET/MRI in Patients With Newly Diagnosed Colorectal Cancer

Status:
Recruiting
Trial end date:
2026-01-01
Target enrollment:
Participant gender:
Summary
This clinical study will investigate the utility of PET imaging with [89Zr]Panitumumab for imaging of EGFR expression in newly diagnosed colon cancer patients to assess lymph node involvement. If promising, this data will be used to design larger trials.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University of Alabama at Birmingham
Treatments:
Antibodies, Monoclonal
Panitumumab